Arkolith/Insider Trading/ADXS/Form 4

Israel Biotech Fund GP Partners, L.P.

Director, 10% OwnerAyala Pharmaceuticals, Inc. (ADXS) · full profile →Form 4 · filed Feb 12, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
8 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 7, 2024Option exercise(M)1.9M$0.40$770K11.0M
Feb 7, 2024Option exercise(M)4.2M$0.40$1.7M18.4M
Feb 7, 2024Option exercise(M)3.9M$0.40$1.6M14.9M
Feb 7, 2024Tax withholding(F)2.6M$1.25$3.2M25.1M
Feb 7, 2024Option exercise(M)8.4M$0.40$3.4M23.4M
Feb 7, 2024Tax withholding(F)2.7M$1.25$3.4M20.7M
Feb 7, 2024Option exercise(M)8.1M$0.40$3.2M27.7M
Feb 7, 2024Option exercise(M)1.3M$0.40$518K19.7M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 7, 2024Option exercise(M)3.9M——11.7M
Feb 7, 2024Option exercise(M)8.1M——13.5M
Feb 7, 2024Option exercise(M)1.3M——14.8M
Feb 7, 2024Option exercise(M)8.4M——7.8M
Feb 7, 2024Option exercise(M)1.9M——13.7M
Feb 7, 2024Option exercise(M)4.2M——19.0M

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001178913-24-000480) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML